Skip to main content
Clinical Trials/NCT05782491
NCT05782491
Withdrawn
N/A

Rapid Progression of Care in Cardiogenic Shock - Awake Surgical Placement of the Impella 5.5 Using Regional Anesthesia

University of Pennsylvania2 sites in 1 countryApril 2024

Overview

Phase
N/A
Intervention
Not specified
Conditions
Cardiogenic Shock
Sponsor
University of Pennsylvania
Locations
2
Primary Endpoint
Success of Using Regional Anesthesia for Impella 5.5 Placement
Status
Withdrawn
Last Updated
last year

Overview

Brief Summary

The Abiomed Impella 5.5 is a surgically placed temporary mechanical support device used in patients in cardiogenic shock. The investigators propose using regional anesthesia (3 separate peripheral nerve blocks) to facilitate Impella 5.5 placement, a procedure which has traditionally been performed under a general anesthetic.

Regional anesthesia is a proven and widely used technique to facilitate upper extremity vascular surgery cases (i.e. arteriovenous fistula creation). The investigators believe that employing these blocks in conjunction with intravenous sedation or monitored anesthesia care (MAC anesthesia) - a technique used in all types of cases, even in sick hearts during thranscatheter aortic valve replacements (TAVR) - will avoid the need increased doses of medications to support the blood pressure and cardiac output, avoid the need for post operative mechanical ventilation and intravenous sedation, and speed up the time to participating in physical therapy, time to heart transplant/durable mechanical support/recovery, and time to hospital discharge.

Detailed Description

General anesthesia places patients who are in cardiogenic shock at risk for life threatening hemodynamic compromise due to the anesthetic and positive pressure ventilation, and confers the need for mechanical ventilation and sedation post operatively. Our hypothesis is that by utilizing regional anesthesia, anesthesiologists can facilitate surgical Impella placement with less risk of cardiovascular collapse with a faster road to recovery. By avoiding endotracheal intubation and concomitant heavy sedation both in the operating room and ICU, these patients will avoid worsening deconditioning and ICU delirium, with less days to physical therapy, ambulation, and recovery as compared to patients who undergo general anesthesia and remain ventilated in the ICU after their Impella placement. Patients scheduled for Impella 5.5 placement will be screened by a specific set of inclusion/exclusion criteria for potential participation in the study. If they consent, they will receive three commonly used upper extremity nerve blocks (Interscalene, PECS II, and superficial cervical plexus nerve blocks) and receive only intravenous sedation during the procedure.

Registry
clinicaltrials.gov
Start Date
April 2024
End Date
July 18, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Baseline Criteria:
  • Agrees to procedure
  • Excellent ultrasound images for nerve blocks
  • Excellent ultrasound images for trans thoracic echo
  • Age \<60, BMI \<30
  • Non hostile neck
  • Evaluation of CT amenable to easy surgical access for Impella placement
  • Meets criteria for MAC sedation:
  • Able to lay relatively flat comfortably
  • Able to understand and cooperate with procedures

Exclusion Criteria

  • Does not wish to have MAC
  • Does not wish to have Regional Anesthesia
  • BMI \> 30
  • Poor U/S windows for block or TTE
  • Active infection over block area
  • High Oxygen Requirement \>6L NC
  • Known or anticipated difficult airway
  • Unable to lay flat comfortably Unable to cooperate or follow instructions

Outcomes

Primary Outcomes

Success of Using Regional Anesthesia for Impella 5.5 Placement

Time Frame: Day of procedure (1 day)

Number of patients that successfully undergo Impella 5.5. placement with the regional anesthesia protocol

Secondary Outcomes

  • Patient pain scores post operatively(3 days)
  • Time to participation in physical therapy(6 weeks)
  • Time to destination therapy(6 weeks)
  • Pain medication requirement(1 week)
  • Sedation requirement(1 week)

Study Sites (2)

Loading locations...

Similar Trials